# A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

Source: https://onco.cc/trials/nct04488822/  
OnCo record `nct04488822` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pexidartinib in tenosynovial giant cell tumour, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.

## Summary

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT is a phase 3 interventional study registered as NCT04488822 by Daiichi Sankyo Co., Ltd., with 40 participants enrolled, started 2020-09-25 and due to reach its primary completion in 2021-10-27. Interventions recorded: Pexidartinib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04488822
- Phase: 3
- Setting: Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor
- Sponsor: Daiichi Sankyo Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT04488822: https://clinicaltrials.gov/study/NCT04488822

## Connected records

- cancers: [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- drugs: [Pexidartinib](https://onco.cc/drugs/pexidartinib/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct04488822.json